• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Becton, Dickinson and Company Plans Tucson, Arizona, Operational Hub

BD (Becton, Dickinson and Company), a leading global medical technology company, will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona. The project is expected to create approximately 40 new jobs.

The new 120,000 square-foot facility, which will be a hub for the company’s supply chain, serving as a final-stage manufacturing and sterilization center, will be built on approximately 32 acres at the northeast corner of Valencia and Kolb Road. The location is planned to be operational in mid-2022.

“Tucson is the ideal location for critical infrastructure and was selected after a careful review of a number of alternative locations in the southwestern U.S. and Mexico,” said Alexandre Conroy, Executive Vice President, Integrated Supply Chain for BD. “Arizona’s favorable business climate, the strength of its workforce and Tucson’s centrality to other parts of BD’s supply chain were key factors in the decision.”

As part of the company’s response to COVID-19 and commitment to public health, state officials said BD is investing significantly in its in-house capacity for manufacturing and sterilization. This transformational project will become an integral part of the U.S. medical device supply chain and expands the footprint BD already has in Arizona, which includes a $1 billion BD Peripheral Intervention business unit headquartered in Tempe.

"We’re excited to see global innovator BD select Tucson for this new operation," added Sandra Watson, President & CEO of Arizona Commerce Authority. "Arizona has earned a reputation as a hub for biotech and life sciences, thanks to our unique value proposition and the continued investments from industry leaders like BD. We thank the company for its continued commitment to our state.”

Tucson is centrally located between eight of BD’s U.S. major manufacturing plants and three distribution centers. BD selected this specific site in Ward 4 because it sits within compatible existing and planned industrial areas. Sun Corridor, Inc. projects that BD’s investment will have a $122 million economic impact over the next 10 years.

“We were tenacious in our efforts to win this project. BD joins Roche Tissue Diagnostics, Accelerate Diagnostics, HTG Molecular and other companies here doing cutting-edge work to help solve our country’s greatest challenges," noted Joe Snell, President & CEO of Sun Corridor Inc.

BD operates more than 90 medical device and health care technology manufacturing and sterilization facilities globally and has a track record of sustainable operations. This facility will be one of the first in the world with an original design that will meet or exceed the most stringent environmental guidelines and serve as a model for other sites worldwide.

Exclusive Research